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• Aminoglycosides (AG) are antibiotics that lower the accuracy of 
protein synthesis by targeting a highly-conserved RNA helix of the 
ribosomal A-site. The discovery of AGs that selectively target the 
eukaryotic ribosome, but lack activity in prokaryotes, are promising 
as antiprotozoals for the treatment of neglected tropical diseases, and 
as therapies to read-through point-mutation genetic diseases. However, 
a single nucleobase change A1408G in the eukaryotic A-site leads to 
negligible affinity for most AGs. Herein we report the synthesis of 6’-
fluoro sisomicin, the first 6’-fluorinated aminoglycoside, which, 
selectively interacts with the protozoal cytoplasmic rRNA A-site, but 
not the bacterial cytoplasmic A-site based on the respective X-ray co-
crystal structures. The disposition 6’-F sisomicin within the bacterial 
and protozoal A-sites respectively reveal that fluorine acts only as an 
H-bond acceptor to favorably interact with G1408 of the protozoal A-
site. Unlike aminoglycosides containing a 6’-amino group, 6’-F 
sisomicin cannot form a pseudo pair with A1408 of the bacterial A-
site, which usually also benefits from additional hydrogen bonds. 
Based upon these structural observations it may be possible to shift 
the antibacterial activity of classical aminoglycosides to act 
preferentially as antiprotozoals. These findings expand the repertoire 
of small-molecules targeting the eukaryotic ribosome and demonstrate 
the usefulness of fluorine as a design element. 
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Introduction 
Aminoglycosides composed of two to four sugar rings with positively 
charged ammonium groups anchored on a deoxystreptamine core are among 
the major classes of marketed antibiotics used worldwide for more than half 
a century.[1,2] The aminoglycosides target an RNA molecular switch in the 
bacterial ribosomal tRNA acceptor site (A-site) and disrupt the fidelity of the 
decoding process in translation.[3] The binding modes of aminoglycosides 
such as paromomycin, geneticin (G418) and sisomicin within the double-
stranded RNA helix of the bacterial A-site have been extensively 
investigated at the atomic level by X-ray analysis.[4-6] Relying on extensive 
structural information, collaborative efforts by our research groups have 
focused on the design and semi-synthesis of several aminoglycoside analogs 
intended to improve antibacterial activity and minimize toxicity to 
mammals.[7-13] Among the sugar rings present in aminoglycosides, ring I 
plays the most important role in the binding specificity to the ribosomal A-
site in bacteria, owing to its deep placement within the double-stranded RNA 
and the internal loop, where it participates in a stable pseudo base-pair 
interaction through two hydrogen bonds with the nucleobase A1408 (E. coli 
ribosomal RNA numbering).[4-6] The rRNA sequence of the bacterial and 
protozoal A-sites are identical with the exception of A1408 that is replaced 
by a guanosine in the protozoal cytoplasmic ribosomal A-site.(Figure 1)[4-
6,14] Interestingly, bacteria can develop ribosomes that are resistant to 
multiple aminoglycoside classes, whereby the pseudo base-pair is altered by 
mutating the adenine nucleobase A1408 to a guanine in the chromosomal 
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16S rRNA loci,[14] or by enzymatic methylation to N1-methyl-adenine.[15] 
Other prevalent mechanisms of bacterial resistance also target the common 
ring I of aminoglycosides, such as enzymatic O-phosphorylation of the 3’-
hydroxyl group, thus abrogating the specific interactions with A1408.[16] 
Although aminoglycosides are generally known for their antibacterial 
activity, they have valuable attributes that can be used against some 
important protozoal and fungal infections.[17] In fact, the naturally occurring 
aminoglycoside paromomycin is a widely used antiprotozoal agent in 
India.[18,19] Since eukaryotes commonly possess a guanine nucleobase at the 
1408 position of the cytoplasmic ribosomal RNA (E. coli ribosomal RNA 
numbering), only a few aminoglycoside antibiotics containing an 6’-OH in 
ring I, such as geneticin (G418) and paromomycin, can bind to the eukaryotic 
ribosomal A-sites,[14,17,20]  while other aminoglycosides such as neomycin 
with a 6’-NH3
+ group, for example, cannot (Figure 1).  Based upon these 
structural observations, we recently reported the synthesis of 6’-OH 
sisomicin, where the 6’-amino group was replaced by a hydroxyl (Figure 
2).[21]  X-Ray analysis of this compound in complex with the protozoal A-
site reveals a pseudo base-pair with G1408 through two hydrogen bonds and 
one C-H…O interaction.(Figure 2) As a consequence, the 6’-OH behaves as 
the acceptor of a hydrogen bond as exemplified by an O6’…H-N2G1408 
interaction (Figure 3). 21 Moreover, we corroborated that 6’-OH sisomicin 
exhibited antiprotozoal activity against several pathogenic species.[21] On the 
other hand, an aminoglycoside with a 6’-NH3+ in ring I cannot participate in 
a pseudo base-pair with G1408, because the NH3
+ group can only behave as 
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a hydrogen bond donor (Figure 3). In 1978, Mallams and coworkers[22] 
isolated 6’-OH sisomicin as a minor hydrolysis byproduct from a naturally 
occurring dimeric aminoglycoside named 66-40C.[22,23] Biological testing 
revealed that 6’-OH sisomicin had reduced antibacterial activity compared 
to sisomicin. However, 6’-OH sisomicin did show improved antibiotic 
potency against a resistant strain of E. coli carrying an AAC(6’) enzyme 
isoform. This was not unexpected since this enzyme is involved in the 
acetylation of the 6’-NH3+ group in sisomicin and related aminoglycosides 
which is now replaced by a 6”-hydroxyl group. It is of interest in the context 
of the work presented herein, that 6’-OH sisomicin exhibited antiprotozoal 
activity against Trichomonas vaginalis, Entamoeba histolytica (JH strain) 
comparable to paromomycin, which suggested that the sisomicin scaffold is 
a good starting point for the design of antiprotozoal aminoglycosides.[21,22]  
The translation accuracy of the human cytoplasmic ribosome is also 
diminished by aminoglycosides that bind the eukaryotic A-site, which has 
promising applications for the treatment of rare genetic diseases caused by 
single point mutations that functionally ablate a protein.[24-28] For example, 
aminoglycoside-induced translational read-through of a premature STOP 
codon in the Cystic Fibrosis Transmembrane Conductance Regulator 
(CFTR) gene is thought to allow a portion of the truncated protein to reach 
its functional mature state.[24-28] 
In view of the potential emergence of resistant ribosome variants in 
bacterial strains, the need for anti-parasitic medications, and a multitude of 
biomedical applications, the discovery of a new generation of semi-synthetic 
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aminoglycosides that could selectively target ribosomal A-sites harboring a 
G1408 nucleobase would be of particular interest.  
In the present study, we have designed and synthesized a sisomicin 
derivative with a fluorine atom at the 6’ position instead of the 6’-amino 
group based on the assumption that the fluorine atom in 6’-F sisomicin would 
behave only as the acceptor of a hydrogen bond and interact favorably with 
G1408 in the cytoplasmic A-site of protozoa. In a previous study, we 
observed an F…H-N hydrogen bond interaction between a fluoro-amino N-
acyl appendage on the deoxystreptamine core unit of a neomycin analog 
within the bacterial A-site, in which the F atom behaved as the hydrogen-
bond acceptor.[13] Therefore, we hypothesized that 6’-F sisomicin would 
preferentially interact with G1408 of the protozoal cytoplasmic rRNA A-site 
and not with A1408 in the bacterial A-site. In order to obtain comparative 
data, we carried out the X-ray analyses of 6’-F sisomicin bound to both the 
bacterial and protozoal cytoplasmic rRNA A-sites to demonstrate which 
variant results in more effective interactions. This property in turn would 
augur well for the development of a eukaryotic-selective aminoglycoside. 
The synthesis of 6'-F sisomicin is shown in Scheme 1. 
 
 
Results 
Overviews of the bacterial and protozoal cytoplasmic A-site structures in 
complex with 6’-F sisomicin  
Crystal structures of 6’-F sisomicin bound to the bacterial and protozoal 
cytoplasmic rRNA A-sites, labeled “BACT/F-sisomicin” and “PROTO/F-
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sisomicin” (Table 1), respectively, were obtained using A-site RNA models 
used in our previous studies (Figure 4).[4-15] In BACT/F-sisomicin and 
PROTO/F-sisomicin crystals, the asymmetric unit consisted of one and one-
half palindromic RNA duplex containing two A-site internal loops, 
respectively. 
In the case of the BACT/F-sisomicin complex (Figure 4, left), only 
one of the two A-site internal loops in the palindromic RNA duplex was fully 
resolved, owing to disordered electronic density assigned to the A1492 and 
A1493 nucleobases that bulge out of the helix (Supplementary Figure 1). 6’-
F Sisomicin was observed occupying only the well-defined A-site internal 
loop mimicking the “on” state of the A-site helix with fully bulged-out 
A1492 and A1493. However, 6’-F sisomicin was not observed in the second 
identical binding pocket.  
In the case of the PROTO/F-sisomicin crystal (Figure 4, right), we 
observed the two protozoal A-site internal loops were occupied by 6’-F 
sisomicin bound within the helix and fixing the A-site in the “on” state with 
nucleobases A1492 and A1493 bulging out. Binding mode of 6’-F sisomicin 
within the A-site helices is almost identical with those of other 4,5-
disubstituted aminoglycosides. [29,30] 
 
Binding pose of 6’-F sisomicin within the bacterial A-site 
6’-F Sisomicin interacts with the bacterial A-site through eight canonical 
hydrogen bonds, two bifurcated hydrogen bonds and one C-H…O 
interaction (Figure 5a). Similarly to the X-ray co-crystal structures for the 
8 
 
parent sisomicin and 6’-OH sisomicin (Supplementary Figure 2 and 3),[6,21] 
the unsaturated ring I of 6’-F sisomicin stacks on top of the nucleobase 
G1491 making a π-π interaction. However, unlike other analogs, the ring I 
of 6’-F sisomicin forms a different type of pseudo base-pair with A1408 only 
through bifurcated hydrogen bonds, F6’…H-N6A1408 and O5’…H-N6A1408 
(Figure 5a). Therefore, the 6’-F atom behaves as an acceptor of a hydrogen 
bond, causing a shift in the register of the pseudo base-pair. In the cases of 
sisomicin and 6’-OH sisomicin, the respective 6’-NH3+ and 6’-OH functional 
groups of ring I behave as hydrogen-bond donors to the N1 atom of A1408. 
(Figure 3)  Aminoglycosides having a hydrogen bond donor in the 6’ 
position of ring I are known to form pseudo base-pairs with A1408 through 
two hydrogen bonds, O5’…H-N6A1408 and N6’/O6’-H…N1A1408 which are 
required to place ring I in the optimal position for a stacking interaction with 
the nucleobase G1491 (Figure 5 and Supplementary Figures 2). Ring II of 
6’-F sisomicin makes direct interactions with the bacterial A-site through 
four hydrogen bonds, N3-H…N7G1494, N3-H…OP2G1494, N3-H…OP1A1493 
and N1-H…O4U1495. Ring III forms four hydrogen bonds to the A-site, O2’’-
H…O6G1405, N3’’-H…N7G1405, N3’’-H…OP2G1405 and O4’’-H…OP2U1406. 
The aforementioned interactions observed for rings II and III of 6’-F 
sisomicin are conserved in X-ray co-crystal structures of the parent sisomicin 
and its 6’-OH derivative in the bacterial A-site (Figure 5a and Supplementary 
Figure 2).  
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Binding pose of 6’-F sisomicin within the protozoal cytoplasmic A-site 
The palindromic RNA duplex models of the bacterial and eukaryotic A-sites 
are identical, with the exception of the A1408G substitution. Therefore, 
almost all interactions observed between 6’-F sisomicin within the bacterial 
A-site are conserved in the PROTO/F-sisomicin complex (Figure 5). The 
major difference is found in the geometry of the pseudo base-pair between 
ring I and nucleobase G1408 that characterizes the protozoal cytoplasmic 
ribosome. In this case, ring I forms a pseudo base-pair with G1408 through 
two hydrogen bonds and one C-H…O interaction, F6’…H-N2G1408, O5’…H-
N1G1408 and C1’-H…O6G1408 (Figure 5b). Therefore, the 6’-F atom behaves 
as the acceptor of a hydrogen bond in the protozoal cytoplasmic rRNA A-
site. Importantly, this pseudo base-pair geometry is essentially identical to 
that observed in 6’-OH sisomicin bound to the protozoal cytoplasmic A-site, 
where 6’-OH behaves as the acceptor of hydrogen bond and makes a 
O6’…H-N2G1408 hydrogen bond (Figure 3 and Supplementary Figure 4). On 
the other hand, ring I of sisomicin with a 6’-NH3+ is less likely to participate 
in a pseudo base-pair with G1408, since the NH3
+ group can only behave as 
the donor of a hydrogen bond (Figure 3). Indeed, our laboratory has made 
numerous attempts to assemble co-crystals of sisomicin with the eukaryotic 
A-site RNA model, which to this date have proven unsuccessful or have led 
to unoccupied A-site RNAs. 
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Inhibitory activities of sisomicin and 6’-F sisomicin against prokaryotes 
and eukaryotes 
The inhibitory activities of the parent sisomicin and 6’-F sisomicin 
against pathogenic bacterial species (MIC) and pathogenic protozoal species 
(EC50) are summarized in Table 2. Validating our hypothesis, 6’-F sisomicin 
exhibited antiprotozoal activity comparable to the natural aminoglycoside 
paromomycin, but it was devoid of antibacterial or bacteriostatic activity 
relative to sisomicin in prokaryotic assays (MICs > 1.0 µg/mL). As expected, 
the parent sisomicin displayed good Gram-negative or Gram-positive 
bacteria (MIC values << 1.0 µg/mL). Moreover, there was no evidence of 
overt toxicity associated with sisomicin or 6’-F sisomicin treatments to the 
HeLa mammalian cell line. These results should be taken in consideration in 
the context of our previous observations with 6’-NH3+ and 6’-OH sisomicin 
analogs,[13] as well as the structurally matching 6’-NH3
+ and 6’-OH 
neomycin-paromomycin pair of naturally occurring aminoglycosides.[17] 
To the best of our knowledge, there are no reports on the antiprotozoal 
activity of sisomicin. Based upon the computationally modeled structure 
shown in Figure 3, sisomicin should not be able to form a pseudo base pair 
with G1408, since the 6’-NH3+ group can only behave as a donor of hydrogen 
bonds. We were therefore surprised, that sisomicin displayed activity against 
protozoal species (Trypanosoma brucei brucei, T. brucei rhodesiense, T. 
cruzi and Leishmania major).  
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Discussion 
Based on the crystal structures of 6’-F sisomicin bound to the bacterial and 
protozoal cytoplasmic A-sites (Figure 5), and the previously reported crystal 
structure of the parent sisomicin bound to the bacterial ribosome A-site[6] 
(Supplementary Figure 2a), we hypothesized that: (i) interactions of 6’-F 
sisomicin with the bacterial ribosome A-site should be disrupted due its 
inability to form a stable pseudo base-pair interaction with the A1408 
nucleobase. Interestingly, the X-ray co-crystal structure of 6’-F sisomicin in 
complex with the palindromic RNA duplex comprising two identical 
bacterial A-sites displays a pose for the 6’-F ring I that was out of register 
with the highly specific hydrogen-bond and stacking interactions made by 
numerous aminoglycoside antibiotics (ii) 6’- F-sisomicin should exhibit 
antiprotozoal activity due to its H-bond acceptor ability with G1408.. (iii) 
the parent sisomicin should experience ineffective binding to the protozoal 
cytoplasmic ribosome A-site, since the 6-NH3
+ in ring I would act as a 
hydrogen bond donor and cannot form a pseudo base-pair with the G1408.  
We observed that the 6’-F sisomicin possesses moderate antiprotozoal 
activity (Table 2), which is favorably comparable to the antileishmanial drug 
paromomycin.[17] However, contrary to paromomycin or sisomicin, which in 
agreement with published data, display a strong antibacterial activity,[22] 6’-
F sisomicin does not display any significant antibacterial or bacteriostatic 
activity, either against laboratory generated E. coli and methicillin-sensitive 
or -resistant S. aureus strains (MIC > 1.0 μg/mL, Table 2). Therefore, it can 
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be concluded that 6’-F sisomicin is not an active antibiotic, and represents a 
novel example of a eukaryote-selective aminoglycoside.  
Contrary to the predictions of the X-ray structural information,  
sisomicin displays a strong baseline activity as an antiprotozoal, even though 
its ring I with an 6’-NH3+ group is not likely to form a high-affinity pseudo 
base-pair with G1408 within the protozoal cytoplasmic ribosome A-site 
(Figure 3). Indeed, these data suggest that sisomicin with four positively-
charged NH3
+ groups may have an advantage in cellular uptake and/or may 
bind to alternative sites besides the protozoal rRNA A-site. These poorly 
studied interactions should be considered for higher-charge aminoglycosides 
that could presumably disturb the process of translation and/or ribosomal 
assembly processes as reported for prokaryotic and eukaryotic full 
ribosomes.[31,32] We contend that 6’-F sisomicin is less likely to engage in 
such unspecific and off-target mechanisms, since the original positively-
charged NH3
+ group in the parent sisomicin, which is exclusively an H-bond 
donor, was replaced by a F atom that is exclusively an H-bond acceptor. 
More broadly, the 6’-fluorine substitution concept to replace a bioactive 
equivalent hydroxyl compound is easily generalizable and such may prove 
to be promising for optimization and development of eukaryote-selective 
antiprotozoal treatments. 
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Conclusions 
We have successfully developed a protozoal-selective aminoglycoside 
exemplified by 6’-F sisomicin relying on a structure-based design approach 
inspired by X-ray crystallographic data. We have confirmed that 6’-F 
sisomicin is effective against pathogenic protozoal species, but largely 
ineffective as an antimicrobial compound against Gram-negative and Gram-
positive bacterial species. To the best of our knowledge, 6’-F sisomicin is 
the first semisynthetic aminoglycoside displaying such a stark reversal of 
selectivity between eukaryote and prokaryote species.[46] The present study 
expands the scope of small-molecule drugs targeting the eukaryotic 
ribosomal A-site and demonstrates the usefulness of fluorine as a design 
element to specifically control hydrogen-bonding interactions of ligands 
with functional RNA biomedical targets. 
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Experimental section  
6’-Fluoro-sisomicin  
Following the procedure reported by Hanessian et al (Scheme 1),[23] 
sisomicin sulfate (1) was converted to 1,3,2',6'-tetraazido-3''-N-Fmoc-
sisomicin (2), and treated under optimized selenium dioxide allylic oxidation 
conditions to yield 6'-aldehydo-1,3,2'-triazido-3''-N-Fmoc sisomicin (3). The 
6'-aldehyde intermediate was subsequently reduced to afford 6'-hydroxy-
1,3,2'-triazido-3''-N-Fmoc sisomicin (4) using sodium borohydride in 
THF/MeOH as previously reported.[13] A solution of the above compound 
(41.2 mg, 0.055 mmol) in CH2Cl2 (100 mL) was treated with KF (6.4 mg, 
0.11 mmol) followed by a solution of Phenofluor® (0.1 M in toluene, 1.1 
mL), and then treated with of N,N-diisopropylethylamine (DIPEA, 17.4 L, 
0.11 mmol). The reaction mixture was stirred overnight at room temperature 
under an argon atmosphere. The crude mixture was filtered through a Teflon 
filter and concentrated under reduced pressure. The residue was purified by 
flash chromatography (2% MeOH in CH2Cl2) affording the fluorinated 
product 5 (23.4 mg, 0.031 mmol, 57%) that was used in the next step without 
further characterization. 
The aforementioned compound 5 (23.4 mg, 0.031 mmol) was 
dissolved in MeOH (900 L), and treated with piperidine (32 L, 0.33 
mmol), a solution of PMe3 (1.0 M in THF, 495 L, 496 mmol) and NH4OH 
(conc., 100L) added sequentially, and the reaction mixture stirred at room 
temperature overnight. The mixture was concentrated under reduced 
pressure and the residue dissolved in a minimum amount of water. The crude 
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mixture was loaded to an ion exchange column containing Amberlite® 
IRC50 (1 mL) and eluted sequentially with water (15 mL), 0.1 N aqueous 
NH4OH (18 mL) and 0.3 N aqueous NH4OH (30 mL). The tubes containing 
the desired product were combined, concentrated to a minimum volume 
under reduced pressure and lyophilized affording the title compound as the 
free base (7.5 mg, 0.0167 mmol of a glassy solid). The product thus obtained 
was dissolved in an aqueous solution of (NH4)2SO4 (100 l, 44 mg 
(NH4)2SO4/mL water, 2 equiv.) and stirred 5 minutes. The mixture was 
lyophilized overnight affording 6’-F sisomicin sulfate (6) as an amorphous 
solid (8.9 mg, 0.014 mmol, 45%, 26% two steps). 
1H NMR (500 MHz, D2O) δ 5.63 (d, J = 2.0 Hz, H-1’), 5.31 (dt, J = 
5.4, 3.8 Hz, H-4’), 5.14 (d, J = 3.7 Hz, H-1’’), 3.96 (d, J = 47.5 Hz, H-6’b), 
3.94 (d, J = 47.5 Hz, H-6’a), 4.23 (dd, J = 10.9, 3.7 Hz, H-2’’), 4.03 (d, J = 
12.9 Hz, H-5’’b), 4.00 (dd, J = 10.4, 8.8 Hz, H-5), 3.86 (td, J = 6.5, 2.1 Hz, 
H-2’), 3.78-3.83 (m, H-4 and H-5), 3.61-3.52 (m, H-3 and H-1), 3.50 (d, J = 
13.4 Hz, H-5’’a), 3.50 (d, J = 10.7 Hz, H-3’’), 2.93 (s, 3H, C-Me), 2.64 (m, 
H-3’b), 2.58 (dt, J = 12.6, 4.3 Hz, H-2b), 2.41 (dddd, J = 17.7, 10.0, 6.8, 3.6 
Hz, H-3’a), 1.95 (q, J = 12.6 Hz, H-2a), 1.35 (s, 3H, N-Me); 13C NMR (126 
MHz, D2O) δ 145.5 (d, 2J5’,F = 14.5 Hz, C-5’), 101.2 (C-1’’), 96.7 (C-1’), 
83.4 (C-6), 82.0 (d, 1J6’a,F = 160.1 Hz), 79.8 (C-5), 73.5 (C-4), 70.0 (C-4’’), 
67.8 (C-3’’), 66.4 (C-2’), 63.4 (C-5’’), 49.9 and 48.3 (C-1 and C-3), 46.1 (C-
2’), 34.6 (N-Me), 27.6 (C-2), 22.1 (C-3’), 21.0 (C-Me); 19F NMR (471 MHz, 
D2O) δ -213.38 (tddd, J = 47.5, 10.0, 8.6, 5.4 Hz); HRMS (ESI-TOF) m/z 
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[M + H]+  Calc. for C19H36FN4O7 451.25625, observed 451.25632, m/z [M 
+ K]+  Calc. for C19H35FKN4O7 489.21214, observed 489.21214. 
 
Crystallizations, Data Collections and Structure Determinations 
For the present crystallographic studies, RNA duplexes containing two A-
site internal loops were designed (Figure 4). These RNA oligomers were 
synthesized by GeneDesign, Inc. (Osaka, Japan), purified by 20% denaturing 
polyacrylamide gel electrophoresis and desalted by reversed-phase 
chromatography. Single crystals of these RNA duplexes in complex with 6’F 
sisomicin (BACT/F-sisomicin and PROTO/F-sisomicin, respectively) were 
obtained in conditions summarized in Table 3. Fresh crystals were mounted 
in nylon cryoloops (Hampton Research) with the crystallization droplet 
containing 40% (v/v) 2-methyl-2,4-pentanediol as a cryoprotectant and 
stored in liquid nitrogen prior to X-ray experiment. X-ray data were collected 
at the NW-12A and BL-17A beamlines in the Photon Factory (Tsukuba, 
Japan). These datasets were processed with the program XDS.[33] These 
obtained intensity data were further converted to structure-factor amplitudes 
using TRUNCATE from the CCP4 suite.[34] The statistics of data collection 
and the crystal data are summarized in Table 1. The initial phases of both the 
BACT/F-sisomicin and PROTO/F-sisomicin crystals were determined by 
the molecular replacement method with the program AutoMR from the 
Phenix suite[35,36] The molecular structures were constructed and 
manipulated with the program Coot.[37,38] The atomic parameters were 
refined with the program phenix.refine from the Phenix suite[35,39] through a 
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combination of simulated-annealing, crystallographic conjugate gradient 
minimization refinements and B-factor refinement. The statistics of structure 
refinements are summarized in Table 1. The atomic coordinates of the 
BACT/F-sisomicin and PROTO/F-sisomicin complexes were deposited to 
the Protein Data Bank (PDB) with ID codes 5Z1H and 5Z1I, respectively.  
 
Cell culture and Cytotoxicity assays 
The determination of the EC50 of the compounds using Alamar Blue was 
completed as previously described.[40,41] Briefly, DMSO solutions of the 
compounds were added to the media and a two-fold serial dilution done 
across a 96-well plate in quadruplicate (12-point serial dilution). Cells were 
counted using a CASY Cell Counter and seeded at cell densities given below. 
After 3 days, 10 mL Alamar Blue (12.5 mg resazurin salt in 100 mL PBS) 
was added to all wells and incubated for a further 6-8 h. Cell viability was 
quantified using an FLx 800 plate reader (BioTek) with excitation 
wavelength 540/35 nm and emission wavelength at 590/10 nm using Gen5 
Reader Control 2.0 Software (BioTek). EC50 values were determined using 
a 4-parameter logistic regression equation using GraFit 5.0 (Erithacus 
Software). 
Bloodstream-form T. brucei brucei strain 427 and were grown in 
HMI-9 media supplemented with 10% foetal bovine serum and 2.5 μg/mL 
G418 at 37 °C with 5% v/v CO2 and seeded at 1 × 10
3 cells/well. T. brucei 
rhodesiense (strain Z310) were cultured in a similar manner, but in the 
absence of G418. 
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HeLa cells (ATCC® CCL-2) were cultured in Dulbecco’s Modified 
Eagle Medium supplemented with 10% foetal bovine serum and grown at 
37°C in 5% CO2 atmosphere and seeded at 1 × 10
3 cells per well. 
Mid-log promastigote L. major MHOM/IL/80/Friedlin were grown at 
28°C in M199 media (pH 7.4), supplemented with 40 mM HEPES pH 7.4, 
100 μM adenosine, 5 μg/mL haemin and 10% heat-inactivated foetal bovine 
serum and seeded at 2 × 105 cells per well. 
Mid-log epimastigote Trypanosoma cruzi CL Brener strain were 
grown at 28°C in RPMI 1640 medium supplemented with 20 mM HEPES 
(pH 7.2), 4.9 mg/mL tryptone, 2 mM sodium glutamate, 2 mM sodium 
pyruvate, 100 μg/mL streptomycin and 100 U/mL penicillin, 20 μg/mL 
haemin and 10% heat-inactivated foetal bovine serum and seeded at 5 × 105 
cells per well.  
 
Plasmodium falciparum growth inhibition assays 
P. falciparum 3D7 (obtained from MR4-ATCC) parasites were cultured with 
human erythrocytes (group B; 3-4% hematocrit) in RPMI medium (Sigma) 
supplemented with 10% AB+ human serum incubated at 37oC in an 
atmosphere of 92% N2, 3% O2, and 5% CO2 using standard methods.
[42] 
Synchronized cultures were obtained by 5% sorbitol lysis.[43] For standard 
growth inhibition assays, parasitemia was adjusted to 0.5-1% with more than 
90% of parasites at the ring stage after sorbitol synchronization. Two 
hundred microliters of parasite cultures were plated in 96-well plates and 
incubated for 48 h at 37°C in the presence of the different compounds to be 
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tested at different concentrations in triplicate. Parasitemia was then 
determined as described by Aguilera et al,[44] briefly, fluorescence-assisted 
cell sorting (FACS). Noninfected RBCs and samples containing parasitized 
RBCs (including controls without tested compounds) were diluted to a final 
concentration of 1 to 10 × 106 cells/mL. The cell suspension was stained with 
SYTO 11 (0.5 mM stock in DMSO, Molecular Probes, Life Technologies) 
to a final concentration of 0.5 μM. Samples were analyzed in a BD 
LSRFortessa cell analyzer (BD; Becton, Dickinson and Company) equipped 
with a high throughput sampler. Excitation of the sample was done using a 
488 nm, air-cooled, argon-ion laser at 15 mW power using forward and side 
scatter to gate the RBC population, and SYTO 11 green fluorescence (530 
nm, FITC filter) was collected in a logarithmic scale. The single-cell 
population was selected on a forward-side scattergram, and the green 
fluorescence from this population was analyzed. Parasitemia was expressed 
as the number of parasitized cells per 100 erythrocytes. Statistical analyses 
were performed using GraphPad Prism v5. 
 
Antibacterial testing 
Compounds were tested against Escherichia coli strain DH5 and 
Staphylococcus aureus strains RN4220 (NCTC8325-4, r− m+) and 
MRSA252 (EMRSA-16) and their potency determined by calculating the 
minimum inhibitory concentration (MIC) analysis.[45] Specifically, this was 
achieved using the microdilution broth method where compounds were 
serially diluted in microtiter plates with a concentration range from 500 M 
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to 0.24 M. Each bacterial strain was prepared by inoculation of a colony 
from an agar plate into 10 ml Müller-Hinton broth and cultured at 37°C with 
shaking until a turbidity corresponding to a 0.5-McFarland suspension 
(OD600nm = 0.1, equivalent to 2 107 CFU/mL S. aureus and 6 107 CFU/mL 
E. coli) was reached. The bacterial inoculum was added to the microtiter 
plate to give a concentration of 5 × 105 CFU/mL in a final volume of 0.1 mL. 
Microtiter plates were sealed to prevent desiccation and incubated overnight 
at 37°C before determination of the MIC value, the lowest concentration of 
compound that inhibited complete growth of the microorganisms as detected 
by eye. For further confirmation, the turbidity of each well was accurately 
measured at 620 nm using a Thermo Scientific Multiskan FC plate reader. 
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Table 1. Crystal data and statistics of data collections and structure refinements. 
 BACT/F-sisomicin PROTO/F-sisomicin 
PDB-ID 5Z1H 5Z1I 
Crystal data   
Space group P21 I422 
Unit cell (Å, °) a = 42.9, b = 31.7, c = 46.7, β = 94.8 a = b = 46.2, c = 115.3 
Z a 1 0.5 
Data collection   
Beamline NW-12A of PF BL-17A of PF 
Wavelength (Å) 1.0 0.98 
Resolution (Å) 42.8-2.4 42.9-1.9 
of the outer shell (Å) 2.5-2.4 2.0-1.9 
Unique reflections 5052 5236 
Completeness (%) 99.7 99.8 
in the outer shell (%) 100.0 99.2 
Rmerge 
b (%) 8.4 7.2 
in the outer shell (%) 27.2 27.5 
Redundancy 3.5 12.0 
in the outer shell 3.6 11.4 
Wilson B-factor 39.4 20.7 
Structure refinement   
Resolution range (Å) 42.8-2.4 42.9-1.9 
Used reflections 5052 5223 
R-factor c (%) 21.3 19.2 
Rfree 
d (%) 26.3 21.1 
Number of RNA atoms 893 451 
Number of ligand atoms 31 31 
Number of water 87 73 
Average B-factor 41.2 25.5 
  of RNA atoms 41.9 24.7 
  of ligand atoms 26.8 20.1 
  of water 38.6 32.4 
R.m.s.d. bond length (Å) 0.007 0.006 
R.m.s.d. bond angles (°) 1.0 1.0 
a Number of RNA duplex in the asymmetric unit. 
b Rmerge = 100  Σhklj|Ihklj – <Ihklj>| / Σhklj<Ihklj>. 
c R-factor = 100  Σ||Fo| – |Fc|| / Σ|Fo|, where |Fo| and |Fc| are optimally scaled observed and calculated structure factor 
amplitudes, respectively. 
d Calculated using a random set containing 10% of observations. 
 
 
Table 2. Inhibitory activities of the parent sisomicin and 6’-F sisomicin against prokaryote (MIC) and 
eukaryote (EC50) 
   sisomicin 6’-F sisomicin 
(Bacteria)   
E. coli DH5 0.14 µg/mL N.S. c 
S. aureus RN4220 a 0.56 µg/mL N.S. c 
S. aureus MRSA252 (EMRSA-16) b 0.56 µg/mL N.S. c 
(Protozoa)   
T. brucei. brucei 4.34 ± 0.27 μM 18.92 ± 0.61 μM 
T. brucei. rhod. 3.92 ± 0.17 μM 17.74 ± 0.82 μM 
T. cruzi 3.28 ± 0.18 μM 10.95 ± 0.44 μM 
L. major 2.02 ± 0.17 μM 20.14 ± 1.3 μM 
P. falciparum - > 25 μM 
(Mammals)   
Mammalian HeLa > 500 μM ~400 μM 
a) S. aureus RN4220 – A methicillin sensitive laboratory strain of NCTC8325, a 
clinical isolate from 1960). 
b) S. aureus MRSA252 (EMRSA-16) – A-methicillin resistant pathogenic 
hospital-acquired strain (clonal complex 30 isolated in 1997) 
c) N.S. No MIC values of significance were obtained by testing the bacterial 
strains with 6’-F sisomicin (> 1.0 µg/mL) 
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Table 3. Crystallization conditions. 
Crystal code BACT/F-sisomicin PROTO/F-sisomicin 
Temperature 293 K 293K 
Sample solution (1 μl)   
RNA 1 mM 1 mM 
6’-F sisomicin 2 mM 2 mM 
Sodium cacodylate (pH = 7.0) 50 mM 50 mM 
Crystallization solution (1μl)   
Sodium cacodylate (pH = 7.0) 50 mM 50 mM 
Spermine tetrahydrochloride 1 mM 1 mM 
Lithium chloride 10 mM 100 mM 
2-Methyl-2,4-pentanediol  1% 1% 
Reservoir solution (250 μl)   
2-Methyl-2,4-pentanediol 40% 40% 
Crystals 
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Figure 1. Secondary structures of the bacterial and protozoal cytoplasmic A-sites (R = A or G, Y = C or U, 
N-N = Watson-Crick base pair). The rRNA nucleobases are numbered according to the numbering used in 
E. coli 16S rRNA. The A/G1408, G/R1491, A1492 and A1493 nucleobases are colored in orange, green, 
blue and red, respectively. 
 
 
 
 
Figure 2. Chemical structures sisomicin, and its derivatives 6’-OH sisomicin[21] and 6’-F sisomicin.  
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Figure 3. Pseudo base-pairs between the 1408 nucleobase in the prokaryotic (A1408) and eukaryotic 
cytoplasmic (G1408) A-sites and ring I of sisomicin and 6’-OH sisomicin observed in crystal structures 
(PDB-ID = 4F8U and 4GPX) or computationally modeled structures. Hydrogen bonds and C-H…O 
interactions are shown as bold and thin dashed lines, respectively. 
 
 
 
 
Figure 4. Overall structures of the bacterial and protozoal cytoplasmic A-sites in complex with 6’-F 
sisomicin (BACT/F-sisomicin and PROTO/F-sisomicin, respectively). A crystallographic two-fold axis 
located at the center of the PROTO/F-sisomicin crystal is indicated by black oval. 
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Figure 5. Binding of 6’-F sisomicin to the bacterial and protozoal cytoplasmic A-sites. Overviews (top), 
pseudo base-pairs between A/G1408 and ring I (middle) and detailed interactions of 6’-F sisomicin to the 
A-sites (bottom) are shown. The A/G1408, G1491, A1492 and A1493 nucleobases are colored in orange, 
green, blue and red, respectively. In the top figures, local |Fo|-|Fc| omit maps calculated after removing 6’-
F sisomicin are drawn in dark blue at 3 σ contour level. Hydrogen bonds and C-H…O interactions are 
shown as bold and thin dashed lines with distances in Å, respectively. 
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Scheme 1. Synthesis of 6’-F sisomicin based on our reported 6’-allylic oxidation[23] of sisomicin.  
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